Literature DB >> 23518766

Investigating the relationship between foveal morphology and refractive error in a population with infantile nystagmus syndrome.

Natasha Healey1, Eibhlin McLoone, Gerald Mahon, A Jonathan Jackson, Kathryn J Saunders, Julie F McClelland.   

Abstract

PURPOSE: We explored associations between refractive error and foveal hypoplasia in infantile nystagmus syndrome (INS).
METHODS: We recruited 50 participants with INS (albinism n = 33, nonalbinism infantile nystagmus [NAIN] n = 17) aged 4 to 48 years. Cycloplegic refractive error and logMAR acuity were obtained. Spherical equivalent (SER), most ametropic meridian (MAM) refractive error, and better eye acuity (VA) were used for analyses. High resolution spectral-domain optical coherence tomography (SD-OCT) was used to obtain foveal scans, which were graded using the Foveal Hypoplasia Grading Scale. Associations between grades of severity of foveal hypoplasia, and refractive error and VA were explored.
RESULTS: Participants with more severe foveal hypoplasia had significantly higher MAMs and SERs (Kruskal-Wallis H test P = 0.005 and P = 0.008, respectively). There were no statistically significant associations between foveal hypoplasia and cylindrical refractive error (Kruskal-Wallis H test P = 0.144). Analyses demonstrated significant differences between participants with albinism or NAIN in terms of SER and MAM (Mann-Whitney U test P = 0.001). There were no statistically significant differences between astigmatic errors between participants with albinism and NAIN. Controlling for the effects of albinism, results demonstrated no significant associations between SER, and MAM and foveal hypoplasia (partial correlation P > 0.05). Poorer visual acuity was associated statistically significantly with more severe foveal hypoplasia (Kruskal-Wallis H test P = 0.001) and with a diagnosis of albinism (Mann-Whitney U test P = 0.001).
CONCLUSIONS: Increasing severity of foveal hypoplasia is associated with poorer VA, reflecting reduced cone density in INS. Individuals with INS also demonstrate a significant association between more severe foveal hypoplasia and increasing hyperopia. However, in the absence of albinism, there is no significant relation between refractive outcome and degree of foveal hypoplasia, suggesting that foveal maldevelopment in isolation does not impair significantly the emmetropization process. It likely is that impaired emmetropization evidenced in the albinism group may be attributed to the whole eye effect of albinism.

Entities:  

Mesh:

Year:  2013        PMID: 23518766     DOI: 10.1167/iovs.12-11537

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Retinal microstructures are altered in patients with idiopathic infantile nystagmus.

Authors:  Jinu Han; Taekjune Lee; Jong Bok Lee; Sueng-Han Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-14       Impact factor: 3.117

Review 2.  Infantile nystagmus: an optometrist's perspective.

Authors:  Asma Aa Zahidi; J Margaret Woodhouse; Jonathan T Erichsen; Matt J Dunn
Journal:  Clin Optom (Auckl)       Date:  2017-09-25

3.  Morphology of foveal hypoplasia: Hyporeflective zones in the Henle fiber layer of eyes with high-grade foveal hypoplasia.

Authors:  Andreas Bringmann; Thomas Barth; Focke Ziemssen
Journal:  PLoS One       Date:  2022-04-13       Impact factor: 3.240

4.  Choroidal and retinal thickness variations in ocular albinism.

Authors:  Ramesh Venkatesh; Sameeksha Agrawal; Nikitha Gurram Reddy; Akhila Sridharan; Joshua Ong; Naresh Kumar Yadav; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

5.  Morphometric analysis of the lens in human aniridia and mouse Small eye.

Authors:  Anna Voskresenskaya; Nadezhda Pozdeyeva; Yevgeniy Batkov; Tatyana Vasilyeva; Andrey Marakhonov; Richard A West; Jeffrey L Caplan; Ales Cvekl; Yan Wang; Melinda K Duncan
Journal:  Exp Eye Res       Date:  2020-11-26       Impact factor: 3.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.